195 results on '"Hahn, Andrew W"'
Search Results
2. Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment Era
3. MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer
4. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance
5. Correction: Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time Among People with HIV in the Current Treatment Era
6. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones
7. Drug and alcohol use among people living with HIV in care in the United States by geographic region
8. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
9. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
10. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
11. Validity Properties of a Self-reported Modified Frailty Phenotype Among People With HIV in Clinical Care in the United States
12. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
13. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma
14. The association of body mass index with tumor aggression among men undergoing radical prostatectomy
15. Development of Frail RISC-HIV: a Risk Score for Predicting Frailty Risk in the Short-term for Care of People with HIV
16. A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates
17. The need for precision medicine in managing cardiovascular risk for men receiving ADT
18. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
19. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
20. Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
21. Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
22. Supplementary Table S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
23. VALIDATION OF A BLOOD-BASED SPHINGOLIPID PANEL FOR MEN WITH LOCALIZED PROSTATE CANCER ON ACTIVE SURVEILLANCE
24. Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo’s Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3–7
25. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
26. Evaluating the Sick Quitting Hypothesis for Frailty Status and Reducing Alcohol Use Among People With HIV in a Longitudinal Clinical Cohort Study
27. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
28. FIGURE 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
29. FIGURE 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
30. Data from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
31. FIGURE 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
32. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
33. FIGURE 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
34. FIGURE 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
35. Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
36. FIGURE 6 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
37. Supplementary Figure 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
38. Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
39. Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
40. Supplementary Figure 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer
41. Venous thromboembolism among people with HIV: Design, implementation, and findings of a centralized adjudication system in clinical care sites across the United States
42. The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms
43. Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV
44. Obesity and renal cell carcinoma: Biological mechanisms and perspectives
45. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
46. Venous Thromboembolism Among People With HIV: Design, Implementation, and Findings of a Centralized Adjudication System in Clinical Care Sites Across the United States.
47. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.
48. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer
49. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome
50. Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.